Hugo F Miranda1, Fernando Sierralta2, Sebastian Lux3, Rocío Troncoso4, Natalia Ciudad3, Ramiro Zepeda5, Pilar Zanetta3, Viviana Noriega6, Juan Carlos Prieto7. 1. Facultad de Medicina, Escuela de Química y Farmacia, Universidad Andrés Bello, Santiago, Chile; Facultad de Medicina, ICBM, Universidad de Chile, Santiago, Chile. Electronic address: hmiranda@med.uchile.cl. 2. Dental School, Universidad Finis Terrae, Santiago, Chile. 3. Facultad de Medicina, ICBM, Universidad de Chile, Santiago, Chile. 4. Facultad de Odontología, Universidad de Chile, Santiago, Chile. 5. Facultad de Medicina, Escuela de Química y Farmacia, Universidad Andrés Bello, Santiago, Chile. 6. Facultad de Medicina, Escuela de Química y Farmacia, Universidad Andrés Bello, Santiago, Chile; Hospital Clínico, Universidad de Chile, Santiago, Chile. 7. Facultad de Medicina, ICBM, Universidad de Chile, Santiago, Chile; Hospital Clínico, Universidad de Chile, Santiago, Chile.
Abstract
BACKGROUND: Pain is one of the most common problems in clinical medicine. There is considerable evidence that pharmacologic approaches are the most widely used therapeutic options to ameliorate persistent or chronic pain. In this study it was evaluated the effect of l-NAME and naltrexone in the antinociception induced by administration of gabapentin in the orofacial formalin test of mice. METHODS: The algesiometer assay was performed by the administration of 20 μl of 2% formalin solution injected into the upper right lip of each mouse. RESULTS: The dose of gabapentin that produces the 50% of the maximum possible effect (ED50) was significantly increased by the pretreatment with l-NAME or naltrexone. CONCLUSIONS: These results suggest that gabapentin produce antinociception partly via the activation nitridergic pathways and opioid system.
BACKGROUND:Pain is one of the most common problems in clinical medicine. There is considerable evidence that pharmacologic approaches are the most widely used therapeutic options to ameliorate persistent or chronic pain. In this study it was evaluated the effect of l-NAME and naltrexone in the antinociception induced by administration of gabapentin in the orofacial formalin test of mice. METHODS: The algesiometer assay was performed by the administration of 20 μl of 2% formalin solution injected into the upper right lip of each mouse. RESULTS: The dose of gabapentin that produces the 50% of the maximum possible effect (ED50) was significantly increased by the pretreatment with l-NAME or naltrexone. CONCLUSIONS: These results suggest that gabapentin produce antinociception partly via the activation nitridergic pathways and opioid system.